Systematic review / meta-analysis / 2017
Niacin therapy did not reduce mortality or cardiovascular events in people with or at risk of CVD and increased side effects.
A systematic review and meta-analysis of 23 RCTs involving 39,195 participants evaluated niacin monotherapy or add-on therapy (median dose 2 g/day, median duration 11.5 months). Niacin did not reduce overall mortality (RR 1.05, 95% CI 0.97 to 1.12), cardiovascular mortality (RR 1.02, 95% CI 0.93 to 1.12), non-cardiovascular mortality (RR 1.12, 95% CI 0.98 to 1.28), fatal or non-fatal myocardial infarctions (RR 0.93, 95% CI 0.87 to 1.00), or strokes (RR 0.95, 95% CI 0.74 to 1.22). Participants receiving niacin were significantly more likely to discontinue treatment due to side effects compared to control (RR 2.17, 95% CI 1.70 to 2.77).
- Study type
- Systematic review and meta-analysis of RCTs
- Who was studied
- 39,195 participants (mean age 33 to 71 years) across 23 RCTs with or at risk of CVD
- What was measured
- Overall mortality, cardiovascular mortality, myocardial infarction, stroke, and side effects
THE PAPER
Niacin for primary and secondary prevention of cardiovascular events.
Schandelmaier S, Briel M, Saccilotto R, Olu KK, Arpagaus A, Hemkens LG, Nordmann AJ. Cochrane Database Syst Rev, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.